49 results about "Molecular Diagnostic Method" patented technology

The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

Disclosed are molecular diagnostic compositions and methods for predicting brain metastasis of breast cancer, as well as methods for drug repositioning to identify existing and new therapeutics for use in developing individualized, patient-specific treatment regimens for improving diagnoses and patient outcomes in individuals at risk for brain metastasis of breast cancer.

The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

The present invention discloses a genotype analysis method for sheep high fecundity gene BMPR1B mutation site A746G. According to the present invention, an allele specific PCR method is adopted to design two groups of primers (the first group of the primers comprises common forward primer and wild type reverse primer, and the second group of the primers comprises common forward primer and mutant reverse primer), a genotype of detected sheep is ++ if a 131 bp DNA fragment is only amplified by using the first group of the primers, a genotype of detected sheep is BB if a 131 bp DNA fragment is only amplified by using the second group of the primers, and a genotype of detected sheep is B+ if a 131 bp DNA fragment is amplified by using the first group of the primers and the second group of the primers. With the present invention, uses of restriction endonucleases and DNA chips in the traditional detection method are avoided, the PCR product is directly subjected to agarose gel electrophoresis analysis to obtain a genotype analysis result, and the genotype analysis method is an accurate, simple and rapid sheep high fecundity gene BMPR1B molecule diagnosis method.

The invention discloses a zika virus nucleic acid detection method based on an electrochemical luminescence amplification principle and belongs to the technical field of zika virus molecular diagnosis. The invention respectively provides the zika virus nucleic acid detection method based on a linear and tree-shaped terpyridyl ruthenium polymer electrochemical luminescence amplification method. The method has the following advantages: 1) high sensitivity; 2) stable probe: the linear and tree-shaped terpyridyl ruthenium polymer used as an electrochemical luminescence amplification part of the probe, stable performance, and uniform degree of polymerization and luminous intensity; 3) simple and quick detection process: the zika virus detection is performed through simple sample pre-treatment and nucleic acid extraction process, time consumption is less, the amplification step is avoided and the detection is quick; 4) low cost. The method disclosed by the invention is a technical system for detecting zika virus nucleic acid; a novel molecular diagnosis method based on the electrochemical luminescence method technique is provided; the defect of single technique for detecting zika virus at present is effectively made up; a zika virus detection method requiring no amplification is supplied.

The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB.

The invention relates to a molecular diagnostic method and kit of genetic bone diseases. The method includes using a capture probe aiming at 561 genetic bone disease related genes and applying a target gene high throughput parallel targeting sequencing method to determine the sequences of the corresponding genes of subjects. The kit includes the capture probe which aims at 561 genetic bone diseaserelated genes. The method has advantages of high throughput, high sensitivity and high singularity; the cost of analyzing pathogenic gene mutation of the genetic bone diseases can be rapidly reduced;and the method has practical clinical significance, is helpful for the drawing of genetic bone disease gene mutation spectrums and the explication of the molecular pathogenesis of the genetic bone diseases, and provides theoretical foundations of early accurate diagnosis, precision treatment, prenatal diagnosis and genetic counseling for the genetic bone diseases.

The invention relates to a diagnosing method and reagent kit for detecting and determining reverse tolerance of helicobacter pylori in gastric biopsy samples. The method can perform a downstream PCR reaction only by simply and directly performing complete genome extraction on biopsy samples of a patient. 23 pairs of primers of which the nucleotide sequences are as shown in figures 2 and 3 are usedfor joint detection of 101 mutation types of common mutation sites of 8 reverse tolerance genes of 23SrRNA,gyrA, PBP1, 16SrRNA, porD, oorD, rpoB and rdxA and two mutation types of a host drug metabolism enzyme CYP2C19 gene so as to perform fast detection and accurate analysis on mutation situation of reverse tolerance genes and drug metabolic enzyme genes of 7 antibiotics which are clinically andfrequently used at present through combination of a nested PCR technique with a sequencing technique, and the specificity and the accuracy are high. Compared with traditional minimal inhibitory concentration culture experiments, the diagnosing method is quicker and acuter in detection, is more suitable for clinical application, and has great clinical application prospects in the respects of guiding individualized diagnosis and treatment of patients being positive in helicobacter pylori.

Lateral flow analysis strips and molecular diagnostic methods using the same are disclosed. The lateral flow analysis strip may comprise a sample pad (100) into which a sample comprising at least one of an amplicon labeled with a label and an amplicon precursor labeled with a label is to be introduced; a conjugate pad (200) comprising a conjugate (C1), the conjugate (C1) having an indicator and a detection agent bound to a surface of the indicator, and the conjugate (C1) being non-fixedly adsorbed to the conjugate pad (200); a test pad (300) comprising a test line (310) to which a first trapping agent is fixed; a control pad (400) comprising a control line (410) to which a second trapping agent is immobilized; and an absorbent pad (500). The lateral flow analysis strip of the present invention can detect amplicons (e.g., nucleic acids) amplified by using an amplicon precursor labeled with a type of label (e.g., a primer or dNTP) and can determine the results directly with the naked eye. Furthermore, the lateral flow analysis strip advanlabel eously has high sensitivity by using the label having a strong binding force, the trapping agent bound to the label , a detection agent, and a trapping agent bound to the detection agent. Further, by using the label having a certain binding force, the trapping agent bound to the label, the detection agent, and the trapping agent bound to the detection agent, the lateral flow analysis strip has reproducible and stable effects.

The invention discloses a molecular diagnosis method for evaluating growth traits based on a copy number variation (CNV) marker of a cattle ZNF146 gene and application of the molecular diagnosis method. Based on real-time quantitative polymerase chain reaction (PCR), by taking cattle genome DNA to be detected as a template, a CNV region of the ZNF146 gene and a partial fragment of the internal reference gene BTF3 are amplified by using two pairs of primers P1 and P2, and finally, a copy number variation type of an individual is calculated and judged by using a 2*2<-delta delta Ct> method. The invention can detect the CNV marker closely related to the cattle growth traits on a DNA level, and the method is simple, is rapid and is convenient to apply and popularize.

The present invention relates to a more accurate method of diagnosing cancer in a tissue or a cell by measuring the expression and activity of cell cycle related proteins and analyzing a cell cycle profile. In a cell cycle profile, at least two values of expression or activity of cell cycle related proteins are concurrently measured. The measurement of the cell cycle related protein is not limited as to the measurement method.

Proposed are an integrated kit for in-situ molecular diagnosis and a molecular diagnosis method using the same. The integrated kit for on-site molecular diagnosis comprises a first assembly and a second assembly, the first assembly comprises a sample pretreatment part, a nucleic acid absorption part and a nucleic acid amplification part, and the second assembly comprises a detection part. The sample pretreatment section includes a transfer member configured to transfer a lysis buffer in which nucleic acid is dissolved, and is configured to pretreat a sample. The nucleic acid absorption portion is positioned on the sample pretreatment portion and configured to be slidable onto the nucleic acid amplification portion. The nucleic acid amplification part is connected to the sample pretreatment part, and is configured to elute the nucleic acid from the nucleic acid absorption part and amplify the eluted nucleic acid. The detection section is configured to transfer the nucleic acid amplified by the nucleic acid amplification section and detect the nucleic acid. The integrated kit for in-situ molecular diagnosis and the molecular diagnosis method using the same according to the present disclosure are advantageous in that the kit enables ordinary people to perform molecular diagnosis without specialized devices (such as a centrifuge or a pipettor), ensures low-pollution operation, and has cost effectiveness.

A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.